Catalyst
Monitor the trial results for 1-year all-cause mortality and readmission rates, as well as any subsequent publications or regulatory filings.
Date
June 18, 2026
Phase
N/A
Status
watch
Signal score
8.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.